Technical Analysis for TSVT - 2seventy bio, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 3.11 | -3.42% | -0.11 |
TSVT closed down 3.42 percent on Wednesday, November 20, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Death Cross | Bearish | 0.00% | |
| New Downtrend | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% |
| Alert | Time |
|---|---|
| Possible NR7 | about 18 hours ago |
| Down 5% | about 19 hours ago |
| 60 Minute Opening Range Breakdown | about 19 hours ago |
| Down 3% | about 22 hours ago |
| Fell Below Previous Day's Low | about 22 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2seventy bio, Inc. operates independently of bluebird bio, Inc. as of November 4, 2021.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Life Sciences Gene Therapy Multiple Myeloma Breakthrough Therapy Chimeric Antigen Receptor T Cell
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Life Sciences Gene Therapy Multiple Myeloma Breakthrough Therapy Chimeric Antigen Receptor T Cell
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.4 |
| 52 Week Low | 1.675 |
| Average Volume | 328,910 |
| 200-Day Moving Average | 4.66 |
| 50-Day Moving Average | 4.64 |
| 20-Day Moving Average | 4.35 |
| 10-Day Moving Average | 3.99 |
| Average True Range | 0.29 |
| RSI (14) | 23.08 |
| ADX | 27.31 |
| +DI | 11.09 |
| -DI | 41.78 |
| Chandelier Exit (Long, 3 ATRs) | 4.43 |
| Chandelier Exit (Short, 3 ATRs) | 3.89 |
| Upper Bollinger Bands | 5.54 |
| Lower Bollinger Band | 3.15 |
| Percent B (%b) | -0.02 |
| BandWidth | 54.96 |
| MACD Line | -0.38 |
| MACD Signal Line | -0.21 |
| MACD Histogram | -0.1703 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.41 | ||||
| Resistance 3 (R3) | 3.41 | 3.32 | 3.36 | ||
| Resistance 2 (R2) | 3.32 | 3.24 | 3.32 | 3.34 | |
| Resistance 1 (R1) | 3.21 | 3.19 | 3.17 | 3.21 | 3.33 |
| Pivot Point | 3.12 | 3.12 | 3.09 | 3.12 | 3.12 |
| Support 1 (S1) | 3.01 | 3.04 | 2.97 | 3.01 | 2.89 |
| Support 2 (S2) | 2.92 | 2.99 | 2.92 | 2.88 | |
| Support 3 (S3) | 2.81 | 2.92 | 2.86 | ||
| Support 4 (S4) | 2.81 |
